“…Regarding the treatment regimens studied, five studies evaluated patients under treatment with capecitabine in combination with other neoplastic agents [ 23 , 24 , 28 , 29 , 30 ], three with capecitabine as monotherapy [ 20 , 27 , 31 ], and five with capecitabine as monotherapy and in combination [ 21 , 22 , 25 , 26 , 32 ]. Five studies only investigated capecitabine PD-related genes [ 20 , 24 , 27 , 29 , 32 ], two only investigated PK-related genes [ 23 , 28 ], and six studied genes related to both [ 21 , 22 , 25 , 26 , 30 , 31 ]. Eight studies evaluated the influence of SNPs on the incidence and severity of capecitabine-induced toxicity [ 21 , 22 , 23 , 25 , 26 , 28 , 31 , 32 ], three assessed the influence of SNPs on the effectiveness of capecitabine-based therapy [ 24 , 27 , 30 ], and two evaluate the influence of SNPs on both toxicity and effectiveness [ 20 , 29 ].…”